941 studies (2 from unattributed sources) on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Polaris Peptides | 26 | 99.51% | View COA → |
| Qingdao Sigma Chemical | 23 | 99.51% | View COA → |
| Peptide Sciences | 21 | 99.71% | View COA → |
| Nexaph | 18 | 98.41% | View COA → |
| Simple Peptide | 16 | 99.86% | View COA → |
| Peptide Crafters | 16 | 99.8% | View COA → |
| (unknown) | 16 | 99.57% | View COA → |
| Aminos Research | 15 | 99.73% | View COA → |
Recent certificates: #63635 (99.885%) · #62991 (99.9%) · #42777 (99.91%) · #22090 (99.8%) · #22091 (99.7%) · #14540 (99.9%)
Manufacturers with published third-party certificates of analysis for Semaglutide. Open a vendor to see every batch we've verified.
Orforglipron significantly reduced **HbA1c** more than oral semaglutide in **type 2 diabetes** patients inadequately controlled with metformin over 52 weeks.
A multicenter observational study aims to compare **Semaglutide**'s weight loss efficacy (hypothesized **4.2 kg**) against other GLP-1 RAs (hypothesized **2.5 kg**) in **Type 2 Diabetes** patients.
The GAPSID study investigates how GLP-1 analogues mechanistically prevent steroid-induced hyperglycemia compared to metformin in pre-diabetic individuals.
Establishing the pharmacokinetic profile of oral semaglutide in patients with **renal impairment** is paramount for optimizing clinical outcomes and patient safety. If kidney dysfunction significantly alters drug expo…
Addressing a critical unmet need, this protocol targets **obese patients on atypical antipsychotics**, particularly those in secure care, where weight gain is severe and lifestyle interventions are challenging. If suc…
If the hypothesis proves true, this study could **redefine the therapeutic landscape for bone health in type 2 diabetes**, offering a novel strategy to mitigate fracture risk using an already established T2D medicatio…
A randomized crossover study will investigate the pharmacokinetics of **semaglutide** and **insulin 287** when administered alone or in combination in **Type 2 Diabetes** patients.
This study underscores that **integrating structured health behavior and lifestyle therapy (HBLT) is crucial for maximizing the effectiveness and adherence of GLP-1RAs like liraglutide in adolescents with obesity**. I…
**GLP-1RAs offer a mechanistically novel therapeutic option for Substance Use Disorders**, targeting central neural reward circuits beyond the scope of existing pharmacotherapies. This opens new avenues for adjunct or…
This case highlights a rare but significant ocular adverse event potentially associated with **semaglutide** dose escalation, urging heightened clinical vigilance. **Healthcare providers should consider atypical optic…
Oral semaglutide (Wegovy) 50 mg once daily showed therapeutic efficacy and a favorable safety profile for chronic weight management in adults with overweight or obesity across OASIS trials.
This review highlights a **critical evidence gap** regarding the direct effects of GLP-1 receptor agonists on thyroid function tests in humans. While large-scale data suggest no increased risk of thyroid malignancy, t…
This Phase II trial positions **BGM0504** as a promising new therapeutic option for **Type 2 Diabetes**, particularly within the Chinese population. The observed dose-dependent `HbA1c` reductions, reaching up to **-2.…
This study provides crucial evidence that a generic **semaglutide** injection is therapeutically equivalent to the innovator product, **Ozempic**, for managing **Type 2 Diabetes Mellitus**. **This finding significantl…
This Fc-binding conjugation strategy offers a broadly applicable method to extend the half-life of peptide therapeutics, potentially reducing injection frequency for patients with **Type 2 diabetes mellitus** and othe…
This study highlights that **semaglutide's benefits extend beyond mere weight loss, significantly improving the subjective experience of 'food noise' and enhancing overall quality of life**. For individuals struggling…
**Integrating semaglutide into pre-ablation protocols could significantly improve long-term rhythm stability for AF patients.** This meta-analysis provides crucial evidence on whether a **GLP-1 receptor agonist** can …
This study provides compelling evidence that prior GLP-1A exposure significantly improves long-term outcomes for **acute ischemic stroke** patients undergoing **endovascular thrombectomy**. For peptide users and clini…
The introduction of disease-modifying therapies like **lecanemab** and **donanemab** represents a critical shift, emphasizing the importance of **early diagnosis** and comprehensive geriatric assessment to balance eff…
For individuals with **diabetes, cardiovascular disease, or cancer**, GLP-1RAs offer a dual benefit of substantial weight loss and reduced cardiovascular risk, reinforcing their role as a cornerstone therapy. While di…
This multicenter study provides compelling evidence that **GLP-1 RAs are a safe and moderately effective therapeutic option for managing post-liver transplant weight gain and improving metabolic health**. Given the hi…
This study provides critical real-world data underscoring the potential risks associated with **semaglutide exposure before and during pregnancy**. For individuals using `GLP-1R` agonists for weight management, these …
This study provides compelling evidence that **semaglutide offers significant cardiovascular protection and metabolic benefits for non-diabetic obese patients following an ACS event and PCI**. The observed **50%** red…
This survey underscores the growing need for **integrated aesthetic management** alongside **GLP-1 agonist** therapy. Clinicians and patients must be prepared for potential aesthetic side effects like facial fat loss …
This case report suggests a rare but important potential side effect of **semaglutide** that clinicians and users should be aware of. **If experiencing unexplained symptoms like galactorrhea, menstrual irregularities,…
This study provides critical molecular insights into how **semaglutide** and **dapagliflozin** exert their kidney-protective effects in **Type 1 diabetes**, specifically within the S3 segment. The distinct and overlap…
**Semaglutide's potential as a dual-target therapy for MAALD could fundamentally reshape how this complex liver disease is managed**, offering a single, potent agent to address both the metabolic dysfunction and the i…
This **Phase 3 trial** is crucial for establishing the long-term cardiovascular safety and efficacy profile of **semaglutide** in **Type 2 Diabetes**. If successful, the findings could further solidify semaglutide's r…
**If NT-0796 proves safe and effective as a semaglutide adjunct, it could offer a significant advancement for individuals with obesity.** This combination therapy might lead to enhanced weight loss, improved metabolic…
If successful, this study could significantly advance the treatment landscape for **adolescent obesity**, providing a much-needed long-term pharmacological option. Current therapies often struggle with sustained effic…
A randomized, placebo-controlled clinical trial is evaluating **semaglutide**'s effect on early liver fibrosis and fat deposition in patients with nonalcoholic fatty liver disease.
Subcutaneous semaglutide will be assessed for safety and efficacy in a new trial targeting Systemic Sclerosis, exploring its potential beyond metabolic indications.
Review synthesizes evidence on *Akkermansia muciniphila*'s role in **Alzheimer's Disease** pathogenesis via the gut-brain axis, immune modulation, and barrier integrity.
**Targeting the redox–mitochondrial axis could offer novel strategies for combating obesity and metabolic disease.** By understanding how this axis drives beige fat immunometabolism and adipose inflammation, researche…
This case underscores the critical importance of **patient education and careful instruction** for individuals self-administering injectable medications like **semaglutide**, particularly when sourced from compounding…
**Cardiometabolic disease management must fundamentally shift from a glucose-centric focus to a comprehensive, organ-protective strategy.** This means clinicians and individuals at risk should consider **SGLT-2 inhibi…
**Semaglutide offers a promising adjunct therapy for selected individuals with Type 1 Diabetes**, potentially improving glycemic control and addressing weight management challenges often associated with insulin therap…
Ellagic acid was investigated for its hepatoprotective effects and modulation of `UPR-PERK` pathway mRNA expression in **metabolic dysfunction-associated fatty liver disease**.
An in vitro study evaluated a standardized phospholipid-formulated bergamot extract for its `GLP-1R`-associated activity, suggesting potential for metabolic health.
If successful, the COMBINE 2 trial could significantly **redefine the treatment paradigm for Type 2 Diabetes**. A once-weekly fixed-ratio combination of **insulin icodec** and **semaglutide** (IcoSema) could offer a p…
If **semaglutide** proves effective as an add-on to SGLT-2i, it could significantly **enhance glycemic control for patients with Type 2 Diabetes** who are not reaching their targets on SGLT-2i alone or in combination …
A study in healthy men compares the bioavailability of **semaglutide** from four different oral tablet formulations to identify optimal drug uptake.
This review underscores the growing importance of **GLP-1**-based medications as a potential cornerstone therapy for patients with **heart failure**, especially those with co-existing **type 2 diabetes** and **obesity…
This study highlights **ellagic acid as a potential complementary therapy for MAFLD**, offering a distinct mechanism of action by targeting the `UPR-PERK` pathway. For individuals managing metabolic dysfunction or MAF…
These findings underscore the complex, reciprocal relationship between insulin and incretin receptor agonists at the **blood-brain barrier**, highlighting potential implications for both therapeutic efficacy and neuro…
This research highlights a critical public health challenge: the growing influence of social media on the unsupervised use of prescription medications like **semaglutide**. For peptide users and biohackers, this under…
The advent of oral GLP-1 RAs represents a significant leap forward, potentially transforming the management of **obesity**, **metabolic syndrome**, and **type 2 diabetes**. **Oral formulations can dramatically improve…
**Accelerating the development and optimization of long-acting injectable (LAI) formulations** is a critical practical takeaway for peptide users and formulators. This interpretable machine learning framework signific…
This research provides a promising platform for overcoming major **GI tract barriers** to oral peptide delivery, potentially expanding the range of therapeutics that can be administered non-invasively. **Developing hi…
Free, no account — handy when you're working with Semaglutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Create free account